Jefferies Financial Group Inc. Takes Position in Collegium Pharmaceutical, Inc. $COLL

Jefferies Financial Group Inc. bought a new position in Collegium Pharmaceutical, Inc. (NASDAQ:COLL) in the 2nd quarter, HoldingsChannel.com reports. The firm bought 27,400 shares of the specialty pharmaceutical company’s stock, valued at approximately $992,000.

A number of other institutional investors and hedge funds also recently modified their holdings of COLL. BlackRock Inc. bought a new position in Collegium Pharmaceutical during the second quarter valued at about $196,972,000. Rubric Capital Management LP increased its position in shares of Collegium Pharmaceutical by 5.3% during the second quarter. Rubric Capital Management LP now owns 3,157,743 shares of the specialty pharmaceutical company’s stock valued at $93,374,000 after buying an additional 157,743 shares during the period. Vanguard Group Inc. boosted its position in shares of Collegium Pharmaceutical by 1.3% in the fourth quarter. Vanguard Group Inc. now owns 2,256,254 shares of the specialty pharmaceutical company’s stock valued at $104,465,000 after acquiring an additional 29,876 shares during the period. Jupiter Topco LLC purchased a new position in Collegium Pharmaceutical during the second quarter valued at approximately $77,743,000. Finally, Janus Henderson Group PLC increased its holdings in Collegium Pharmaceutical by 26.0% during the 1st quarter. Janus Henderson Group PLC now owns 1,825,651 shares of the specialty pharmaceutical company’s stock worth $60,358,000 after acquiring an additional 377,073 shares during the period.

Wall Street Analysts Forecast Growth

Several research analysts have commented on the stock. Wall Street Zen downgraded shares of Collegium Pharmaceutical from a “buy” rating to a “hold” rating in a report on Saturday, August 8th. Truist Financial raised Collegium Pharmaceutical to a “strong-buy” rating in a research note on Monday, June 15th. Needham & Company LLC decreased their target price on Collegium Pharmaceutical from $56.00 to $46.00 and set a “buy” rating on the stock in a research note on Thursday, August 6th. Piper Sandler reaffirmed a “neutral” rating and issued a $43.00 price target (down from $45.00) on shares of Collegium Pharmaceutical in a report on Friday, August 7th. Finally, Weiss Ratings lowered Collegium Pharmaceutical from a “hold (c)” rating to a “hold (c-)” rating in a report on Tuesday, August 11th. One investment analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and three have given a Hold rating to the company. Based on data from MarketBeat, Collegium Pharmaceutical currently has a consensus rating of “Moderate Buy” and an average price target of $51.00.

Collegium Pharmaceutical Stock Performance

Shares of COLL stock opened at $25.35 on Monday. The business has a 50-day moving average price of $32.96 and a two-hundred day moving average price of $34.98. Collegium Pharmaceutical, Inc. has a 12-month low of $25.16 and a 12-month high of $50.79. The company has a quick ratio of 0.84, a current ratio of 1.03 and a debt-to-equity ratio of 3.32. The firm has a market cap of $825.40 million, a P/E ratio of 20.44 and a beta of 0.73.

Collegium Pharmaceutical (NASDAQ:COLL) last announced its quarterly earnings data on Thursday, August 6th. The specialty pharmaceutical company reported $1.92 EPS for the quarter, beating the consensus estimate of $1.72 by $0.20. The firm had revenue of $199.88 million for the quarter, compared to analyst estimates of $199.62 million. Collegium Pharmaceutical had a return on equity of 91.43% and a net margin of 5.93%.The company’s revenue was up 6.3% on a year-over-year basis. During the same period in the prior year, the company earned $1.68 EPS. Equities analysts anticipate that Collegium Pharmaceutical, Inc. will post 6.51 EPS for the current fiscal year.

Collegium Pharmaceutical Profile

Collegium Pharmaceutical, Inc is a specialty pharmaceutical company focused on the development, manufacture and commercialization of products for pain management and opioid dependence. The company’s core expertise lies in its DETERx microsphere technology, a platform designed to provide extended-release delivery of active pharmaceutical ingredients while deterring manipulation for unintended routes of abuse.

The company’s principal marketed products include Xtampza® ER (extended-release oxycodone), which received approval from the U.S.